Cardioxane

Dexrazoxane Hydrochloride is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated in cardiomyopathy and breast cancer and has 11 investigational indications. It is grouped under the following drug class(es): Topoisomerase inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Dexrazoxane hydrochloride, Totect and Savene. Its PubChem CID is 6918223.

CAS No 149003-01-0
Molecular Formula C11H17ClN4O4
Molecular Weight 304.73 g/mol
Synonyms 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione;hydrochloride

Frequently Asked Questions